[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"monoclonal-gammopathy-of-undetermined-significance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:monoclonal-gammopathy-of-undetermined-significance":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,41,68,89,115,137,154,174,214,237,261,285,303,329,353,376],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100559046","determine-the-frequency-of-variants-in-the-gbapsap-genes-in-patients-with-mm-or-mgus-100559046",false,"NCT06559033","Determine the Frequency of Variants in the GBA\u002FPSAP Genes in Patients With MM or MGUS","Determine the Frequency of Variants in the GBA\u002FPSAP Genes in Patients With Multiple Myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)","GAMY","Inclusion Criteria:\n\n* Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (\\>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g\u002FL and no clinical involvement).\n* Membership of a social security scheme\n* Adult having read and understood the information letter and signed the consent form\n\nExclusion Criteria:\n\n* Person deprived of liberty by an administrative or judicial decision or person placed under court protection \u002F sub-guardianship or guardianship",true,"ALL","18 Years",{"count":21,"type":22},300,"ESTIMATED","OBSERVATIONAL","No effective specific treatment is currently available for the management of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS). A better understanding of the pathophysiological mechanisms would make it possible to propose treatments specifically targeting the deregulated pathways.",[26,27],"Monoclonal Gammopathy of Undetermined Significance","Myeloma Multiple","RECRUITING","2026-06-08",{"date":31,"type":32},"2026-06-10","ACTUAL",{"date":34,"type":32},"2025-10-07",{"date":36,"type":22},"2027-04-01",{"name":38,"class":39},"University Hospital, Rouen","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100627295","fast-m-prolonged-overnight-fasting-and-mediterranean-dietary-intervention-for-patients-with-multiple-myeloma-or-its-precursor-disease-100627295","NCT07446777","FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease","Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease (the FAST-M Study)","FAST-M","Inclusion Criteria:\n\n1. 18 years of age or older.\n2. Any sex\u002Fgender.\n3. Able to provide consent.\n4. Able to speak, read, and understand English or Spanish.\n5. Diagnosis of Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), or Multiple Myeloma (MM) per standard criteria:\n\n   1. Cohort 1 - Participants must have a confirmed diagnosis of MGUS and SMM.\n   2. Cohort 2 - Participants must have a confirmed new diagnosis of MM and be initiating anti-myeloma therapy.\n6. Delivery of anti-myeloma therapies at one of the following institutions:\n\n   1. Sylvester Comprehensive Cancer Center (SCCC) (including satellite\u002Fnetwork sites).\n   2. University of Miami Health System.\n7. Approval from treating oncologist, confirmed via email or in writing.\n8. Eastern Cooperative Oncology Group (ECOG) Performance Status grade of \\\u003C2\n\n   a. PI approval needed if ECOG ≥ 2.\n9. Having not consistently (not equal to or more than 50% of the time) engaged in structured fasting (i.e., not regularly fasting for ≥12hr\u002Fnight) for the past 3 months.\n10. Not consuming a Mediterranean diet by not meeting 2 or more out of the following 3 Mediterranean eating pattern goals in the prior 3 months: ≥3 servings of vegetables per day, ≥ 3 servings of beans and legumes per week, or ≥ 1 serving of nuts per day.\n\n    Mediterranean diet will be screened with select components of a Mediterranean Diet Adherence Screener (MEDAS).\n11. Internet access on a smart phone, tablet, or computer.\n12. Willing to be randomized to a prolonged overnight fasting and guided Mediterranean dietary intervention or waitlist-control group.\n\nExclusion Criteria:\n\n1. Individuals younger than 18 years of age.\n2. Unable to provide consent.\n3. Unable to read or understand English or Spanish.\n4. Any contraindication for diet changes as determined by physician.\n5. History of a clinical eating disorder.\n6. History of dementia or major psychiatric disease.\n7. History of recent (≤1 yr) stroke, myocardial infarction or congestive heart failure.\n8. History of autoimmune disease and on treatment at time of screening.",{"count":50,"type":22},120,"INTERVENTIONAL",[53],"NA","The purpose of this study is to find out whether a dietary approach that includes prolonged overnight fasting, guided by a Mediterranean-style eating pattern, is feasible for patients with myeloma precursor disease or newly diagnosed multiple myeloma.",[56,26,57],"Multiple Myeloma","Smoldering Multiple Myeloma","2026-04-27",{"date":60,"type":32},"2026-05-01",{"date":62,"type":32},"2026-04-07",{"date":64,"type":22},"2029-04-30",{"name":66,"class":39},"University of Miami",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":67},"100264823","observational-prospective-research-study-in-monoclonal-gammopathies-leading-to-myeloma-100264823","NCT02726750","Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma","Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma (ORIGIN Study)","Inclusion Criteria:\n\n* Patients with monoclonal gammopathy of unknown significance. Both criteria must be met:\n\n  * Serum monoclonal protein \\\u003C 3 g\u002FdL or urinary monoclonal protein \\\u003C 500 mg per 24 hours and clonal bone marrow plasma cells \\\u003C 10%\n  * Absence of myeloma defining events or amyloidosis\n* Patients with smoldering multiple myeloma. Both criteria must be met:\n\n  * Serum monoclonal protein \\>= 3 g\u002FdL or urinary monoclonal protein \\>= 500 mg per 24 hours and\u002For clonal bone marrow plasma cells 10-60%\n  * Absence of myeloma defining events or amyloidosis\n\nExclusion Criteria:\n\n* Evidence of myeloma defining events or biomarkers of malignancy due to underlying plasma cell proliferative disorder meeting at least one of the following\n\n  * Hypercalcemia: serum calcium \\> 0.25 mmol\u002FL (\\> 1 mg\u002FdL) higher than the upper limit of normal or \\> 2.75 mmol\u002FL (\\> 11 mg\u002FdL)\n  * Renal Insufficiency: creatinine clearance \\\u003C 40 ml\u002Fmin or serum creatinine \\> 2 mg\u002FdL\n  * Anemia: hemoglobin value \\\u003C 10 g\u002FdL or 2 g\u002FdL \\\u003C normal reference\n  * Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized tomography (CT) or 2-deoxy-2\\[F-18\\] fluoro-D-glucose positron emission tomography CT (PET-CT)\n  * Clonal bone marrow plasma cell percentage \\>= 60%\n  * Involved:uninvolved serum free light chain ratio \\>= 100 measured by Freelite assay (The Binding Site Group, Birmingham, United Kingdom \\[UK\\])\n  * \\> 1 focal lesions on magnetic resonance imaging (MRI) studies (each focal lesion must be 5 mm or more in size)\n* Prior or concurrent systemic treatment for asymptomatic monoclonal gammopathies\n\n  * Bisphosphonates are permitted\n  * Radiotherapy is not permitted\n  * Prior treatment with chemotherapy or investigational agents for asymptomatic gammopathies is not permitted\n* Plasma cell leukemia\n* Uncontrolled intercurrent illness including but not limited to active infection or psychiatric illness\u002Fsocial situations that would compromise compliance with study requirements",{"count":76,"type":22},200,"The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.",[26,79],"Smoldering Plasma Cell Myeloma","2026-04-20",{"date":82,"type":32},"2026-04-21",{"date":84,"type":32},"2015-12-14",{"date":86,"type":22},"2028-04-30",{"name":88,"class":39},"M.D. Anderson Cancer Center",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":51,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100488494","a-study-comparing-a-plant-based-diet-with-supplements-and-placebo-in-people-with-monoclonal-gammopathy-of-undetermined-significance-mgus-or-smoldering-multiple-myeloma-smm-100488494","NCT05640843","A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)","A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients With Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - The Nutrition Prevention (NUTRIVENTION-3) Study","Inclusion Criteria:\n\n* Confirmed diagnosis of MGUS or SMM\n* If non light chain MGUS\u002FSMM then M spike must be either ≥ 0.2 g\u002FdL or BM PC ≥10% (both not required)\n* If light chain MGUS\u002FSMM then involved must be ≥10 mg\u002FdL or BM PC ≥10% (both not required)\n* If IgA MGUS\u002FSMM then an IgA level \\>350 mg\u002FdL and an abnormal immunofixation is required (M spike criteria not required).\n* If IgD MGUS\u002FSMM then an IgD level \\>50 mg\u002FdL and an abnormal immunofixation is required (M spike criteria not required).\n* Age ≥18 years\n* Willingness to comply with all study-related procedures\n* ECOG performance status of 0-3\n* Interested in learning to cook plant based recipes\n\nExclusion Criteria:\n\n* Patients that already follow a whole foods plant based diet (ovo-lacto-vegetarian or processed junk food vegan diets are not excluded)\n* Legume allergy\n* Severe allergies such as anaphylactic shock to nuts (specifically cashews). Peanuts are not included in the meals.\n* Concurrent participation in weight loss\u002Fdietary\u002Fexercise programs\n* Mental impairment leading to inability to cooperate\n* Enrollment onto any other therapeutic investigational study concurrently and up to 180 days prior to study start date\n* Concurrent pregnancy\n* Positive HBV, HCV or HIV PCR test will need to be treated first and once undetectable viral load patients may enroll\n* ≥ Grade 2 electrolyte abnormalities as defined by CTCAEv5.0 (need to be resolved before enrolling on study)\n* If in the opinion of the investigator there maybe any concerns regarding the ability of the patient to complete the study safely or any contraindications\n* Heavy drinker (defined as \\>2 drinks per day or \\>14 drinks per week)\n* Current self-reported illicit drug use (eg heroin, cocaine not marijuana)\n* Plan for prolonged travel during the study that would preclude adherence to prescribed diets\n* History of major gastrointestinal surgery (not including appendectomy or cholecystectomy) within 3 months of enrollment\n* If already taking curcumin or omega 3 supplements patients must be willing to stop it on the date of trial consent for study duration.",{"count":97,"type":22},180,[53],"The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare how the plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo (an inactive substance that looks like the study supplements) affect butyrate levels in participants' stool.",[26,57],[102,103,104],"Plant-Based Diet","Supplements","22-175","2026-04-15",{"date":107,"type":32},"2026-04-16",{"date":109,"type":32},"2022-11-29",{"date":111,"type":22},"2026-11",{"name":113,"class":39},"Memorial Sloan Kettering Cancer Center",8,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":122,"enrollmentInfo":123,"targetDuration":125,"studyType":23,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":134,"locationsCount":136},"100545533","promoting-diagnosis-and-management-of-al-in-italy-prodigality-100545533","NCT06383143","Promoting Diagnosis and Management of AL in Italy (ProDigALIty)","ProDigALIty","PART A\n\nInclusion Criteria:\n\n* diagnosis of MGUS with altered FLCR or SMM;\n* treatment-naïve;\n* age ≥18 years;\n* ability to understand and willingness to sign an informed consent;\n* planned follow-up at participating center.\n\nExclusion Criteria:\n\n* Diagnosis of symptomatic monoclonal gammopathies;\n* Previous treatment for monoclonal gammopathies.\n\nPART B\n\nInclusion criteria:\n\n* diagnosis of systemic AL amyloidosis;\n* treatment-naïve;\n* age ≥18 years;\n* ability to understand and willingness to sign an informed consent;\n* planned follow-up at participating center.\n\nExclusion criteria:\n\n* non-AL amyloidosis;\n* previous treatment for AL amyloidosis.","99 Years",{"count":124,"type":22},760,"2 Years","The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to:\n\n1. Implement a biomarker-based screening strategy to promote early diagnosis of AL amyloidosis among at-risk patients, including patients with monoclonal gammopathy of undetermined significance, MGUS, and altered free light chain ratio (aFLCR), and patients with smoldering multiple myeloma (SMM)\n2. Expedite and facilitate patients' referral and their enrollment in ongoing pre-clinical\u002Fclinical studies, also to reflect a broader spectrum of the real-world population of patients with AL amyloidosis in Italy;\n3. Investigate the clinical utility of novel diagnostic technologies, including light chain sequencing and N-glycosylation analysis",[128,57,26],"AL Amyloidosis","2026-04-13",{"date":107,"type":32},{"date":132,"type":32},"2023-05-01",{"date":60,"type":22},{"name":135,"class":39},"Fondazione IRCCS Policlinico San Matteo di Pavia",4,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":67},"100449770","quality-of-life-in-patients-with-asymptomatic-monoclonal-gammopathies-100449770","NCT05136807","Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies","Inclusion Criteria:\n\n* Patients with either monoclonal gammopathy of unknown significance age \\>= 18 years old.\n\n  * Both criteria must be met:\n\n    * Serum monoclonal protein \\\u003C 3 g\u002FdL or urinary monoclonal protein \\\u003C 500 mg per 24 hours and clonal bone marrow plasma cells \\\u003C 10%\n    * Absence of myeloma defining events or amyloidosis\n* OR Patients with smoldering multiple myeloma age \\>= 18 years old.\n\n  * Both criteria must be met:\n\n    * Serum monoclonal protein \\>= 3 g\u002FdL or urinary monoclonal protein \\>= 500 mg per 24 hours and\u002For clonal bone marrow plasma cells 10-60%\n    * Absence of myeloma defining events or amyloidosis\n* Patients must be enrolled in clinical trials for SMM or MGUS at MD Anderson Cancer Center, including protocols PA15-0575 (NCT02726750) (Prospective observational study of clinical and genomic predictors of progression to myeloma in asymptomatic monoclonal gammopathies); 2015-0148 (Phase II single arm trial of Isatuximab in patients with intermediate and high risk smoldering multiple myeloma); and 2015-0371 (NCT02603887) (Pilot single arm, single center, open label trial of Pembrolizumab in patients with intermediate and high risk smoldering multiple myeloma) and any future clinical trials for MGUS and\u002For SMM that open at MD Anderson Cancer Center.\n* Only patients who are English or Spanish speaking are eligible.\n\nExclusion Criteria:\n\n* Evidence of myeloma defining events or biomarkers of malignancy due to underlying plasma cell proliferative disorder meeting at least one of the following\n\n  * Hypercalcemia: serum calcium \\> 0.25 mmol\u002FL (\\> 1 mg\u002FdL) higher than the upper limit of normal or \\> 2.75 mmol\u002FL (\\> 11 mg\u002FdL)\n  * Renal Insufficiency: creatinine clearance \\\u003C 40 ml\u002Fmin or serum creatinine \\> 2 mg\u002FdL\n  * Anemia: hemoglobin value \\\u003C 10 g\u002FdL or 2 g\u002FdL \\\u003C normal reference\n  * Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized tomography (CT) or 2-deoxy-2\\[F-18\\] fluoro-D-glucose positron emission tomography CT (PET-CT).\n  * Clonal bone marrow plasma cell percentage \\>= 60%\n  * Involved: uninvolved serum free light chain ratio \\>= 100 measured by Freelite assay (The Binding Site Group, Birmingham, United Kingdom \\[UK\\])\n  * \\>1 focal lesions on magnetic resonance imaging (MRI) studies, if the patient has an MRI done per eligibility criteria (each focal lesion must be 5 mm or more in size)\n* Plasma cell leukemia.\n* Presence of cognitive impairment or delirium as determined by the primary clinician.",{"count":144,"type":22},400,"This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.",[26,79],"2026-04-10",{"date":105,"type":32},{"date":150,"type":32},"2016-06-07",{"date":152,"type":22},"2027-02-02",{"name":88,"class":39},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":67},"100467049","two-biologically-and-clinically-distinct-entities-progressive-versus-stable-multiple-myeloma-mm-precursor-conditions-100467049","NCT05361694","Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions","Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions (TRANSFORMM)","TRANSFORMM","Inclusion Criteria:\n\n1. Diagnosis of MGUS and SMM will be made in accordance with the clinical diagnostic criteria set forth by the 2014 International Myeloma Working Group (IMWG) Revised Criteria.2\n2. The diagnoses will be confirmed by either serum\u002Furine protein electrophoresis, immunofixation and light-chain assays; or immunohistochemistry analyses of the bone marrow biopsy, or a combination of these tests.\n3. Age greater than or equal to 18 years.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.\n5. The patient must be competent to sign an informed consent form.\n\nExclusion Criteria:\n\n1. A diagnosis of MM as defined as any patient with detectable M-protein in blood and\u002For urine, monoclonal plasma cells in the bone marrow, and evidence of end-organ damage based on the Calcium Elevation, Renal Failure, Anemia, and Bone Disease (CRAB) criteria and\u002For myeloma-defining events.\n\n   * Patients who have received previous therapy for MM.\n   * Patients with known plasma cell or related lymphoid (e.g. lymphoplasmacytic lymphoma, Amyloid Light chain (AL) amyloidosis)\n2. Confirmation of pathological diagnosis is required either from the initial pathology review report or review from the UM\u002FSCCC Hematopathologist in accordance with the clinical diagnostic criteria set forth by the International Myeloma Working Group (IMWG) or World Health Organization (WHO). Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the patient during sampling required for routine patient care or required testing on a University of Miami (UM) \u002FSylvester Comprehensive Cancer Center (SCCC) research protocol will be used for diagnosis.\n3. Active symptomatic major organ disorder that would increase the risk of biopsy or other procedure, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.\n\n   * Active concomitant medical or psychological illnesses that may increase the risk to the patient or inability to obtain informed consent, at the discretion of the Principal Investigator.\n   * Pregnant or breast-feeding women will not be eligible for any aspect of this protocol.\n   * Prisoners will be excluded.",{"count":163,"type":22},1000,"The key aim of the study is to define the two biologically and clinically distinct entities: progressive versus stable myeloma precursor conditions.",[56,57,26],"2026-04-06",{"date":168,"type":32},"2026-04-09",{"date":170,"type":32},"2022-04-12",{"date":172,"type":22},"2027-07-01",{"name":66,"class":39},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":182,"targetDuration":184,"studyType":23,"phases":4,"briefSummary":185,"conditions":186,"keywords":202,"overallStatus":204,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":67},"100513772","clonal-hematopoiesis-of-immunological-significance-100513772","NCT05969821","Clonal Hematopoiesis of Immunological Significance","Immuno-inflammatory Manifestations With or Without Clonal Hematopoiesis: Ambispective Cohort Study","CHIS","Inclusion Criteria:\n\n* Age \\>=18 years old;\n* Confirmed dysimmune manifestations: clinical or biological abnormality or systemic disease;\n* Presence or absence of myeloid or lymphoid blood disease according to World Health Organization (WHO) classification\n\nExclusion Criteria:\n\n* Persons benefiting from special protection: adults under guardianship and curatorship;\n* People hospitalized without their consent and not protected by law; persons deprived of liberty;\n* Persons not affiliated to the social security system",{"count":183,"type":22},5000,"10 Years","Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.",[187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,26],"Immune System Diseases","Autoimmune Diseases","Inflammation","Autoinflammatory Diseases","Vexas Syndrome","Hematopoiesis Clonal","Clonal Hematopoiesis of Indeterminate Potential","Hematologic Diseases","Myelodysplastic-Myeloproliferative Diseases","Leukemia Myelomonocytic Chronic","Myelodysplastic Syndromes","Myeloproliferative Disorders","Lymphoproliferative Disorders","Lymphoma","Leukemia",[189,190,203,188,193,195,199,26],"Vexas syndrome","NOT_YET_RECRUITING","2026-03-19",{"date":207,"type":32},"2026-03-23",{"date":209,"type":22},"2026-04",{"date":211,"type":22},"2045-09",{"name":213,"class":39},"Assistance Publique - Hôpitaux de Paris",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":222,"targetDuration":184,"studyType":23,"phases":4,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":67},"100164029","ohio-state-university-multiple-myeloma-and-amyloidosis-data-registry-and-sample-resource-100164029","NCT01408225","Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource","Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis","B-SCR-MM","Inclusion:\n\nDiagnosis of a plasma cell dyscrasia\n\nExclusion:\n\nPrisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol.",{"count":183,"type":22},"The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals:\n\n* Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live.\n* Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups.\n* Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.",[225,26,128,56],"Plasma Cell Dyscrasias",[227,56,228],"MGUS","Tissue Bank","2026-03-18",{"date":207,"type":32},{"date":232,"type":32},"2011-03-17",{"date":234,"type":22},"2050-03",{"name":236,"class":39},"Ohio State University Comprehensive Cancer Center",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":18,"minAge":244,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":51,"phases":248,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":204,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":67},"100616442","exploring-the-effects-of-korean-style-mediterranean-diet-kormed-and-physical-activity-measurement-in-patients-with-mgussmm-a-pilot-study-100616442","NCT07305662","Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGUS\u002FSMM: A Pilot Study","KORMED-PA Stud","Inclusion Criteria:\n\nParticipants must meet all of the following:\n\nAdults aged 19 to 80 years at the time of enrollment.\n\nDiagnosed with MGUS (Monoclonal Gammopathy of Undetermined Significance) or Smoldering Multiple Myeloma (SMM) according to standard criteria.\n\nAble and willing to follow a Korean-style Mediterranean diet (KORMED) for 12 weeks.\n\nAble to use a smartphone and wearable device to track daily physical activity.\n\nWilling to attend study visits and provide blood, stool, and questionnaire data at scheduled time points.\n\nAble to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Participants will not be eligible if they meet any of the following:\n\nDiagnosis of active multiple myeloma requiring treatment.\n\nCurrent participation in another interventional clinical trial.\n\nSevere liver, kidney, or heart disease that would make the diet or study procedures unsafe.\n\nUncontrolled infection or serious medical condition that may interfere with participation.\n\nHistory of major gastrointestinal surgery that prevents adherence to the diet.\n\nPregnant or breastfeeding, or planning to become pregnant during the study period.\n\nAllergy or intolerance to key components of the KORMED diet (e.g., fish, nuts, legumes) that prevents safe participation.\n\nAny condition, in the investigator's judgment, that would make participation unsafe or limit the ability to complete the study.","19 Years","80 Years",{"count":247,"type":22},20,[53],"This single-arm pilot study aims to evaluate the feasibility and potential health effects of a Korean-style Mediterranean diet (KORMED) and continuous physical activity measurement in patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). The study investigates whether a 12-week KORMED dietary intervention, combined with monitoring of daily step counts using a wearable device, can improve metabolic and inflammatory biomarkers, body composition, gut microbiome diversity, and quality of life.\n\nThe study seeks to answer the following primary question:\n\nIs the KORMED diet feasible and achievable for MGUS\u002FSMM patients, as measured by changes in K-MEDAS adherence scores over 12 weeks?\n\nSecondary questions include:\n\n1. Does adherence to KORMED lead to improvements in BMI, inflammatory markers (CRP, IL-6), metabolic indicators (HOMA-IR, FLI), M-protein levels, and gut microbiome diversity?\n2. Is increased daily physical activity, measured by step counts, associated with favorable changes in metabolic and clinical parameters?\n3. Can combined dietary and activity-based lifestyle modification provide preliminary evidence supporting delayed disease progression in precursor plasma cell disorders?",[26,251],"Smoldering Myeloma","2026-01-20",{"date":254,"type":32},"2026-01-21",{"date":256,"type":22},"2026-01-30",{"date":258,"type":22},"2027-07-15",{"name":260,"class":39},"Seoul National University Bundang Hospital",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":51,"phases":269,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":284},"100520386","a-study-of-a-plant-based-diet-and-dietary-supplements-in-people-with-smoldering-multiple-myeloma-smm-or-monoclonal-gammopathy-of-undetermined-significance-mgus-100520386","NCT06055894","A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)","Microbial Changes in Response to a Plant Based Diet and\u002For Supplements in SMM\u002FMGUS Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via HealthTree","Inclusion Criteria:\n\n* Confirmed prior diagnosis MGUS or of smoldering myeloma (any time prior). However, confirmation of diagnosis must be documented in their last local oncologist clinic note within 6 months prior to study enrollment.\n* Age ≥18 years\n* Willingness to comply with all study-related procedures\n* Physically able to complete requirements for the study or has someone to assist with the requirements (such as meal preparation, stool shipment and survey completion)\n* Interested in learning to cook plant-based recipes\n* Access to smart mobile phone or device with camera and ability to download Keenoa app\n* Be residing within the United States for the study duration.\n* English speaking or a family member or caregiver who speaks English and is able to assist with the surveys and phone based Keenoa app.\n\nExclusion Criteria:\n\n* Taking any supplements other than vitamin D, iron, vitamin B12, potassium, magnesium, calcium or those needed for a medical indication must be reviewed by PI. If patient is on a supplement (including curcumin, probiotic, omega3) they must stop these for 2 weeks prior to enrollment on study.\n* Patients that already follow a whole foods plant based diet (ovo-lactovegetarian or processed junk food vegan diets are not excluded). This will be per research dietitian evaluation and discretion after nutrition screening.\n* Legume allergy\n* Severe allergies such as anaphylactic shock to peanuts and\u002For tree nuts, such as cashews\n* Concurrent participation in weight loss\u002Fdietary trials or defined programs (that require specified diets\u002Fsupplements on the program). Patients on weight loss drugs are eligible.\n* Mental impairment leading to inability to cooperate\n* Enrollment onto any other therapeutic investigational study\n* Concurrent pregnancy\n* Patients on full dose anticoagulation\n* If in the opinion of the investigator there maybe any concerns regarding the ability of the patient to complete the study safely\n* Current self-reported heavy alcohol use and is defined as \\>5 drinks per day or \\>15 drinks per week\n* Current self-reported illicit drug use (except inhaled marijuana, vaping or cigarette smoking or medical marijuana.\n* Has a condition requiring antibiotics within 14 days of study intervention administration.\n* Plan for travel during the study that would preclude adherence to prescribed diets\n* History of active inflammatory bowel disease or major gastrointestinal surgery (not including appendectomy or cholecystectomy) within 3 months of enrollment or any history of total colectomy, or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e. restrictive procedures such as banding, are permitted)",{"count":76,"type":22},[53],"The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. All participants will have smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). The researchers will compare how the different dietary changes affect butyrate levels in participants' stool.",[272,56,26],"Multiple Myeloma, Smoldering",[102,274,275],"Dietary Supplements","23-116","2025-11-12",{"date":278,"type":32},"2025-11-13",{"date":280,"type":32},"2023-09-20",{"date":282,"type":22},"2026-09",{"name":113,"class":39},7,{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":122,"enrollmentInfo":291,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":67},"100371262","sleep-apnea-in-patients-with-mgus-and-mm-100371262","NCT04114084","Sleep Apnea in Patients With MGUS and MM","Patients diagnosed with MGUS or MM who will be receiving a bone marrow biopsy as part of their standard of care are eligible to participate in this study",{"count":76,"type":22},"This study involves patients with plasma cell dyscrasia including monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma (MM), with and without sleep apnea, who are providing bone marrow specimens. Specimens will be obtained at the time that patients undergo a standard-of-care procedure in order to minimize discomfort and reduce any risk.",[56,26],"2025-11-05",{"date":296,"type":32},"2025-11-10",{"date":298,"type":32},"2019-05-23",{"date":300,"type":22},"2030-05-23",{"name":302,"class":39},"Michael Tomasson",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":311,"conditions":312,"keywords":315,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":328},"100584894","whole-body-mri-in-oncology-100584894","NCT06895291","Whole Body MRI in Oncology","ONCO-MRI","Inclusion Criteria:\n\n* Patients candidate to WB-MRI according to clinical practice belonging to the study groups listed above.\n* Participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged ≥ 18 years.\n* Life expectancy greater than 3 months.\n\nExclusion Criteria:\n\n* Patients with MRI-unsafe prostheses and devices.\n* Patients whose tests are of suboptimal quality, or whose test has been suspended, or is incomplete.",{"count":163,"type":22},"Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures\u002Fpatient visits in comparison with the usual clinical practice are planned for the study.",[200,313,314,26,57,56],"Advanced Prostate Cancer","Advanced Breast Cancer",[26,316,317,314,313,200,318],"Smoldering multiple myeloma","Multiple myeloma","Whole Body-Magnetic Resonance Imaging","2025-03-25",{"date":321,"type":32},"2025-03-30",{"date":323,"type":32},"2023-10-26",{"date":325,"type":22},"2031-10",{"name":327,"class":39},"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS",3,{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":337,"conditions":338,"keywords":341,"overallStatus":204,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":67},"100553709","screening-for-monoclonal-gammopathy-in-individuals-undergoing-physical-examinations-using-ims-lc-assay-technology-100553709","NCT06489613","Screening for Monoclonal Gammopathy in Individuals Undergoing Physical Examinations Using iMS-LC Assay Technology.","Inclusion Criteria:\n\n1. Clinical patients:\n\n   * ≥18 years old;\n   * have concurrent SPEP + SIFE + FLC test results.\n2. Individuals undergoing routine physical examinations:\n\n   * ≥30 years old;\n   * have concurrent SPEP test results.\n\nExclusion Criteria:\n\n* NA",{"count":336,"type":22},15600,"iMS-LC Assay (intact M-protein Screening-Light Chain Assay) is a new technology based on mass spectrometry identification of intact clonal immunoglobulin light chains for the specific detection of M-proteins in peripheral blood.\n\nThe investigators propose to conduct a prospective, single-center observational study to screen for M-proteins in the peripheral blood of individuals undergoing routine physical examinations using iMS-LC Assay technology. The goals of this observational study are : (1) to evaluate the diagnostic efficacy of detecting peripheral blood M-proteins using the iMS-LC Assay method; and (2) to determine the prevalence of MGUS in the population undergoing routine physical examinations based on mass spectrometry screening.\n\nInitially, the investigators will collect clinical patient samples continuously and conduct a diagnostic trial of the iMS-LC Assay, using the clinical methods SPEP + SIFE + FLC as the gold standard. Based on the diagnostic performance of the iMS-LC Assay, the investigators will then screen for M-proteins in continuous samples from individuals undergoing routine physical examinations, to further determine the prevalence of MGUS in this population based on mass spectrometry screening.",[339,340,26],"M Protein","Monoclonal Gammopathy",[342,343],"M protein","Monoclonal gammopathy of unknown significance","2024-07-06",{"date":346,"type":32},"2024-07-09",{"date":348,"type":22},"2024-07",{"date":350,"type":22},"2025-06",{"name":352,"class":39},"Jian Li",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":363,"conditions":364,"keywords":365,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":67},"100513411","the-china-m-protein-screening-project-in-first-degree-relatives-of-myeloma-patient---the-chaperone-study-100513411","NCT05965115","The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study","The China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) --A Multicenter Observational Study","CHAPERONE","Inclusion Criteria:\n\n1. Male or female over the age of 18;\n2. First-degree relatives (including parents, children, and biological siblings) have multiple myeloma diagnosed by the International Myeloma Working Group (IMWG) Myeloma Diagnostic Criteria;\n3. Understand the purpose and procedure of this trial and voluntarily participate in this screening study;\n4. Participants should be willing and able to follow the study follow-up plan and other protocol requirements.\n\nExclusion Criteria:\n\nPatients with a known diagnosis of plasma cell diseases, such as MGUS, smoldering myeloma (SMM), or multiple myeloma",{"count":362,"type":22},10000,"The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for monoclonal gammopathy (M-protein) in first-degree relatives of patients with multiple myeloma in China population, and establish a prospective cohort of individuals with monoclonal gammopathy of undetermined significance (MGUS), a precursor conditions to multiple myeloma. We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.",[56,26],[26,56,366],"Early Tumor Screening","2023-07-31",{"date":369,"type":32},"2023-08-01",{"date":371,"type":22},"2023-07",{"date":373,"type":22},"2035-08",{"name":375,"class":39},"Shanghai Zhongshan Hospital",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":204,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":67},"100416458","establishment-of-genomic-transcriptomic-and-functional-characteristics-of-tumor-cells-in-hyperinflammatory-hemopathies-100416458","NCT04702932","Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies","GEN-HEMO-INF","Inclusion Criteria:\n\n* Patient over 18 years of age with the capacity to give express free and informed consent.\n* Patient followed in one of the services participating in the study and meeting the 2 following conditions\n\n  1. have myelodysplastic syndrome, or multiple myeloma, or monoclonal gammopathy of undetermined significance, or Schnitzler's syndrome.\n  2. have a fever of undetermined etiology associated with one of the following symptoms: rash, arthralgia or arthritis, serositis, abdominal pain.\n\nExclusion Criteria:\n\n* Patient incapable of giving express free and informed consent.\n* Subject under guardianship, curatorship or safeguarding of justice.\n* Subject does not speak French.\n* Subject incapable of answering questions or expressing himself\u002Fherself.\n* Presence of a differential diagnosis that may explain the patient's symptoms.",{"count":384,"type":22},30,"Patients with monoclonal gammopathies either benign or malignant may develop inflammatory symptoms such as Schnitzler syndrome. We proposed to name those cases as monoclonal gammopathy of inflammatory significance, or MGIS.\n\nThe aim of the study is to search for inflammatory pathway that may be activated in case MGIS and to search if the genetic of tumoral cell could explain those activations.",[26,56,387],"Waldenstrom Macroglobulinemia",[389,390,317,391],"Autoinflammatory syndromes","Monoclonal gammopathies of unknown significance","Waldenstrom macroglobulinemia","2021-01-08",{"date":394,"type":32},"2021-01-11",{"date":396,"type":22},"2021-09-01",{"date":398,"type":22},"2036-09-01",{"name":213,"class":39}]